Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
Status:
Completed
Trial end date:
2013-09-28
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the rate of early discontinuation from
randomized Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) for any reason
other than confirmation of the negative HIV infection status of the index person in patients
receiving HIV PEP for at least 28 and a maximum of 30 days.